NASDAQ:BLRX - BioLineRx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.91 +0.01 (+1.11 %)
(As of 05/27/2018 05:42 AM ET)
Previous Close$0.91
Today's Range$0.8951 - $0.9493
52-Week Range$0.78 - $1.34
Volume199,770 shs
Average Volume267,910 shs
Market Capitalization$96.91 million
P/E RatioN/A
Dividend YieldN/A
Beta0.53

About BioLineRx (NASDAQ:BLRX)

BioLineRx logoBioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company's other therapeutic candidates comprise BL-1040, a resorbable polymer solution for use in the prevention of ventricular remodeling; BL-9020, which is a monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; and BL-1230, a cannabinoid receptor type 2 intended as an anti-inflammatory treatment for dry eye syndrome. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.

Receive BLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLRX
CUSIPN/A
Phone972-2548-9100

Debt

Debt-to-Equity RatioN/A
Current Ratio7.37
Quick Ratio7.50

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.46 per share
Price / Book1.98

Profitability

EPS (Most Recent Fiscal Year)($0.27)
Net Income$-24,350,000.00
Net MarginsN/A
Return on Equity-47.07%
Return on Assets-41.75%

Miscellaneous

Employees43
Outstanding Shares106,490,000

BioLineRx (NASDAQ:BLRX) Frequently Asked Questions

What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

How were BioLineRx's earnings last quarter?

BioLineRx (NASDAQ:BLRX) announced its earnings results on Tuesday, May, 22nd. The biotechnology company reported ($0.06) EPS for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.01. View BioLineRx's Earnings History.

When is BioLineRx's next earnings date?

BioLineRx is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for BioLineRx.

What price target have analysts set for BLRX?

4 equities research analysts have issued 12-month price targets for BioLineRx's stock. Their forecasts range from $3.00 to $4.00. On average, they expect BioLineRx's stock price to reach $3.25 in the next year. View Analyst Ratings for BioLineRx.

What are Wall Street analysts saying about BioLineRx stock?

Here are some recent quotes from research analysts about BioLineRx stock:
  • 1. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (5/25/2018)
  • 2. Maxim Group analysts commented, "BiolineRx announced long-term follow-up data from the phase 2a study of BL-8040 (CXCR4 antagonist) in relapsed/refractory acute myeloid leukemia (r/ r AML) demonstrating improved overall survival (OS)." (12/4/2017)
  • 3. HC Wainwright analysts commented, "AML Needle Continues to Point in Right Direction; Reiterate Buy Responses appear to impact survival in relapsed or refractory setting. This morning, BioLineRx announced long-term follow-up data from the BL-8040 Phase 2a in relapsed or refractory AML. Recall that in March 2016, topline results (n=42) were presented showing an overall response rate (CR+CRi) of 38%, which compared favorably to a historical control of approximately 20% (HiDAC alone). With longer observation in hand, the company is highlighting data from 16 patients in the expansion phase of the study: 1) median follow-up time of 338 days (29-853 days); 2) median overall survival of 11.1 months; and 3) estimated one- and two-year survival rates of 37.5% and 28.5%, respectively. While these patient numbers continue to be small, they continue to compare favorably with the expected overall survival of 6.1 months for HiDAC." (12/4/2017)

Are investors shorting BioLineRx?

BioLineRx saw a decrease in short interest in April. As of April 13th, there was short interest totalling 402,992 shares, a decrease of 24.7% from the March 30th total of 535,186 shares. Based on an average daily volume of 171,670 shares, the days-to-cover ratio is presently 2.3 days.

Who are some of BioLineRx's key competitors?

Who are BioLineRx's key executives?

BioLineRx's management team includes the folowing people:
  • Mr. Philip A. Serlin, Chief Exec. Officer (Age 58)
  • Ms. Mali Zeevi, CFO & Principal Accounting Officer (Age 42)
  • Dr. Ella Sorani Ph.D., VP of Devel. (Age 50)
  • Dr. Abi Vainstein-Haras M.D., VP of Clinical and Medical Affairs (Age 43)
  • Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 66)

Has BioLineRx been receiving favorable news coverage?

News coverage about BLRX stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioLineRx earned a news sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of BioLineRx?

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $0.91.

How big of a company is BioLineRx?

BioLineRx has a market capitalization of $96.91 million. The biotechnology company earns $-24,350,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. BioLineRx employs 43 workers across the globe.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-2548-9100 or via email at [email protected]


MarketBeat Community Rating for BioLineRx (BLRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  469
MarketBeat's community ratings are surveys of what our community members think about BioLineRx and other stocks. Vote "Outperform" if you believe BLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioLineRx (NASDAQ:BLRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for BioLineRx in the last 12 months. Their average twelve-month price target is $3.25, suggesting that the stock has a possible upside of 257.14%. The high price target for BLRX is $4.00 and the low price target for BLRX is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.25$3.25$3.25$3.20
Price Target Upside: 257.14% upside225.00% upside200.93% upside181.94% upside

BioLineRx (NASDAQ:BLRX) Consensus Price Target History

Price Target History for BioLineRx (NASDAQ:BLRX)

BioLineRx (NASDAQ:BLRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2018HC WainwrightSet Price TargetBuy$4.00LowView Rating Details
12/21/2017OppenheimerInitiated CoverageBuy$3.00MediumView Rating Details
12/4/2017Maxim GroupSet Price TargetBuy$3.00LowView Rating Details
8/9/2017Roth CapitalSet Price TargetBuy$3.00LowView Rating Details
2/13/2017Rodman & RenshawInitiated CoverageBuy$3.00N/AView Rating Details
9/23/2016S&P Equity ResearchLower Price Target$1.24 ➝ $1.10N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

BioLineRx (NASDAQ:BLRX) Earnings History and Estimates Chart

Earnings by Quarter for BioLineRx (NASDAQ:BLRX)

BioLineRx (NASDAQ:BLRX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.23)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.05)($0.05)($0.05)
Q2 20181($0.06)($0.06)($0.06)
Q3 20181($0.06)($0.06)($0.06)
Q4 20181($0.06)($0.06)($0.06)

BioLineRx (NASDAQ BLRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/22/20183/31/2018($0.07)($0.06)ViewListenView Earnings Details
3/6/2018Q4 2017($0.06)($0.07)ViewN/AView Earnings Details
11/21/2017Q3 2017($0.05)($0.07)ViewN/AView Earnings Details
8/8/20176/30/2017($0.05)($0.05)$0.01 millionViewListenView Earnings Details
5/25/20173/31/2017($0.05)($0.08)$0.01 millionViewN/AView Earnings Details
3/23/201712/31/2016($0.08)($0.13)$0.02 millionViewN/AView Earnings Details
11/22/2016Q316($0.07)($0.08)ViewN/AView Earnings Details
8/11/2016Q216($0.07)($0.07)ViewListenView Earnings Details
5/17/2016Q116($0.08)($0.10)ViewListenView Earnings Details
3/10/2016Q415($0.06)($0.07)ViewListenView Earnings Details
11/16/2015Q315($0.08)($0.03)ViewListenView Earnings Details
8/20/2015Q215($0.10)($0.09)ViewListenView Earnings Details
5/18/2015Q115($0.10)($0.08)ViewListenView Earnings Details
4/13/2015Q4 2014($0.10)($0.11)ViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.02)ViewN/AView Earnings Details
8/6/2014Q214($0.09)($0.12)ViewN/AView Earnings Details
5/20/2014Q114($0.11)($0.01)ViewN/AView Earnings Details
3/17/2014($0.15)($0.20)ViewN/AView Earnings Details
11/13/2013($0.18)($0.20)ViewN/AView Earnings Details
8/6/2013Q213($0.02)ViewN/AView Earnings Details
5/7/2013($0.02)($0.20)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.29)($0.30)ViewN/AView Earnings Details
11/14/2012Q312($0.15)ViewN/AView Earnings Details
8/15/2012Q2 2012($0.25)($0.02)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.30)ViewN/AView Earnings Details
3/22/2012Q4 2011($0.30)ViewN/AView Earnings Details
11/29/2011Q3 2011($0.20)ViewN/AView Earnings Details
8/23/2011Q2 2011($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioLineRx (NASDAQ:BLRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioLineRx (NASDAQ BLRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 35.72%
Insider Trading History for BioLineRx (NASDAQ:BLRX)
Institutional Ownership by Quarter for BioLineRx (NASDAQ:BLRX)

BioLineRx (NASDAQ BLRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

BioLineRx (NASDAQ BLRX) News Headlines

Source:
DateHeadline
Q2 2018 Earnings Forecast for BioLineRx Issued By Oppenheimer (BLRX)Q2 2018 Earnings Forecast for BioLineRx Issued By Oppenheimer (BLRX)
www.americanbankingnews.com - May 25 at 6:37 AM
Oppenheimer Brokers Increase Earnings Estimates for BioLineRx (BLRX)Oppenheimer Brokers Increase Earnings Estimates for BioLineRx (BLRX)
www.americanbankingnews.com - May 24 at 9:52 AM
BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2018 Results - Earnings Call TranscriptBioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 22 at 5:12 PM
HC Wainwright Analysts Give BioLineRx (BLRX) a $4.00 Price TargetHC Wainwright Analysts Give BioLineRx (BLRX) a $4.00 Price Target
www.americanbankingnews.com - May 22 at 2:57 PM
BioLineRx (BLRX) Announces Quarterly  Earnings Results, Beats Expectations By $0.01 EPSBioLineRx (BLRX) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 22 at 1:35 PM
Biolinerx reports Q1 resultBiolinerx reports Q1 result
seekingalpha.com - May 22 at 8:15 AM
Form 6-K BioLineRx Ltd. For: May 22Form 6-K BioLineRx Ltd. For: May 22
www.streetinsider.com - May 22 at 8:15 AM
BioLineRx (BLRX) Tops Q1 EPS by 1cBioLineRx (BLRX) Tops Q1 EPS by 1c
www.streetinsider.com - May 22 at 8:15 AM
BioLineRx Reports First Quarter 2018 Financial ResultsBioLineRx Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 22 at 8:15 AM
BioLineRx (BLRX) Expected to Post Earnings of -$0.07 Per ShareBioLineRx (BLRX) Expected to Post Earnings of -$0.07 Per Share
www.americanbankingnews.com - May 18 at 7:18 AM
Form 6-K BioLineRx Ltd. For: May 17Form 6-K BioLineRx Ltd. For: May 17
www.streetinsider.com - May 17 at 7:00 PM
BRIEF-Biolinerx To Present Overall Survival Data At Eha From Phase 2A Study Of Bl-8040 In R/R Aml PatientsBRIEF-Biolinerx To Present Overall Survival Data At Eha From Phase 2A Study Of Bl-8040 In R/R Aml Patients
www.reuters.com - May 17 at 7:00 PM
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone ...BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone ...
www.prnewswire.com - May 17 at 7:00 PM
BioLineRx (BLRX) Announces Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell MobilizationBioLineRx (BLRX) Announces Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization
www.streetinsider.com - May 17 at 7:00 PM
BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML PatientsBioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients
finance.yahoo.com - May 17 at 7:00 PM
BioLineRx (BLRX) Set to Announce Quarterly Earnings on TuesdayBioLineRx (BLRX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 17 at 9:14 AM
BRIEF-Biolinerx Announces Grant Of European Patent Covering Use Of Bl-8040 With CytarabineBRIEF-Biolinerx Announces Grant Of European Patent Covering Use Of Bl-8040 With Cytarabine
www.reuters.com - May 16 at 8:13 AM
BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid ...BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid ...
www.prnewswire.com - May 16 at 8:13 AM
BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid LeukemiaBioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
finance.yahoo.com - May 16 at 8:13 AM
BioLineRx to Report First Quarter 2018 Results on May 22, 2018BioLineRx to Report First Quarter 2018 Results on May 22, 2018
finance.yahoo.com - May 16 at 8:13 AM
BioLineRx (BLRX) Given Average Recommendation of "Buy" by AnalystsBioLineRx (BLRX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 13 at 7:39 PM
BioLineRx (BLRX) Raised to Hold at Zacks Investment ResearchBioLineRx (BLRX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - May 8 at 6:58 PM
BioLineRx (BLRX) Raised to Sell at ValuEngineBioLineRx (BLRX) Raised to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 10:32 PM
BioLineRx (BLRX) Short Interest UpdateBioLineRx (BLRX) Short Interest Update
www.americanbankingnews.com - April 29 at 1:16 AM
BioLineRx (BLRX) PT Set at $3.00 by Maxim GroupBioLineRx (BLRX) PT Set at $3.00 by Maxim Group
www.americanbankingnews.com - April 19 at 12:16 PM
BioLineRx (BLRX) Receives Consensus Recommendation of "Hold" from BrokeragesBioLineRx (BLRX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 18 at 7:24 PM
BioLineRx (BLRX) Upgraded at ValuEngineBioLineRx (BLRX) Upgraded at ValuEngine
www.americanbankingnews.com - April 17 at 10:55 PM
Contrasting BioLineRx (BLRX) & resTORbio (TORC)Contrasting BioLineRx (BLRX) & resTORbio (TORC)
www.americanbankingnews.com - April 15 at 5:18 PM
BioLineRx (BLRX) Expected to Announce Earnings of -$0.07 Per ShareBioLineRx (BLRX) Expected to Announce Earnings of -$0.07 Per Share
www.americanbankingnews.com - April 13 at 7:13 PM
Roth Capital Analysts Give BioLineRx (BLRX) a $3.00 Price TargetRoth Capital Analysts Give BioLineRx (BLRX) a $3.00 Price Target
www.americanbankingnews.com - April 12 at 5:07 PM
Bioline RX (BLRX) Upgraded by Zacks Investment Research to BuyBioline RX (BLRX) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 8 at 10:08 AM
Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)
finance.yahoo.com - April 3 at 5:39 PM
Active-Investors: Wired News - vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 DiabetesActive-Investors: Wired News - vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 Diabetes
www.finanznachrichten.de - March 27 at 8:20 AM
Wired News – vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 DiabetesWired News – vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 Diabetes
finance.yahoo.com - March 27 at 8:20 AM
BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid TumorsBioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors
finance.yahoo.com - March 26 at 8:16 AM
Bioline RX Ltd (BLRX) Receives Average Recommendation of "Hold" from AnalystsBioline RX Ltd (BLRX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 7:33 PM
BioLineRx to Present at the 28th Annual Oppenheimer Healthcare ConferenceBioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 14 at 8:25 AM
Bioline RX Ltd (BLRX) Expected to Post Earnings of -$0.07 Per ShareBioline RX Ltd (BLRX) Expected to Post Earnings of -$0.07 Per Share
www.americanbankingnews.com - March 10 at 3:22 PM
FY2018 EPS Estimates for Bioline RX Ltd Cut by Oppenheimer (BLRX)FY2018 EPS Estimates for Bioline RX Ltd Cut by Oppenheimer (BLRX)
www.americanbankingnews.com - March 9 at 10:54 AM
Zacks Investment Research Lowers Bioline RX (BLRX) to SellZacks Investment Research Lowers Bioline RX (BLRX) to Sell
www.americanbankingnews.com - March 8 at 6:41 PM
Oppenheimer Weighs in on Bioline RX Ltds FY2022 Earnings (BLRX)Oppenheimer Weighs in on Bioline RX Ltd's FY2022 Earnings (BLRX)
www.americanbankingnews.com - March 8 at 2:58 PM
BioLineRx Reports Year End 2017 Financial Results - PR Newswire - PR Newswire (press release)BioLineRx Reports Year End 2017 Financial Results - PR Newswire - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:12 AM
BioLineRxs (BLRX) CEO Philip Serlin on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaBioLineRx's (BLRX) CEO Philip Serlin on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 7 at 8:12 AM
Bioline RX (BLRX) Given Buy Rating at HC WainwrightBioline RX (BLRX) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - March 6 at 3:28 PM
Form 6-K BioLineRx Ltd. For: Mar 06 - StreetInsider.comForm 6-K BioLineRx Ltd. For: Mar 06 - StreetInsider.com
www.streetinsider.com - March 6 at 8:11 AM
BioLineRx Reports Year End 2017 Financial ResultsBioLineRx Reports Year End 2017 Financial Results
finance.yahoo.com - March 6 at 8:11 AM
Bioline RX Ltd Sponsored ADR to Host Earnings CallBioline RX Ltd Sponsored ADR to Host Earnings Call
finance.yahoo.com - March 6 at 8:11 AM
Bioline RX Ltd (BLRX) Receives Consensus Recommendation of "Buy" from BrokeragesBioline RX Ltd (BLRX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 27 at 7:28 PM
BioLineRx to Report Annual 2017 Results on March 6, 2018BioLineRx to Report Annual 2017 Results on March 6, 2018
finance.yahoo.com - February 27 at 8:13 AM
Bioline RX Ltd (BLRX) Expected to Post Earnings of -$0.06 Per ShareBioline RX Ltd (BLRX) Expected to Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - February 21 at 9:20 PM

SEC Filings

BioLineRx (NASDAQ:BLRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioLineRx (NASDAQ:BLRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioLineRx (NASDAQ BLRX) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.